Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Malignant Melanoma

  Free Subscription


28.06.2021

1 Anticancer Res
2 Clin Cancer Res
1 Gene
2 J Am Acad Dermatol
1 J Clin Oncol
3 Oncogene
1 PLoS One
1 Proc Natl Acad Sci U S A


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Anticancer Res

  1. DEBICKA-KUMELA M, Romanowska-Dixon B, Karska-Basta I, Kowal J, et al
    Diagnostic Algorithm for Conjunctival Melanocytic Lesions.
    Anticancer Res. 2021;41:3161-3167.
    PubMed         Abstract available


    Clin Cancer Res

  2. ASCIERTO PA, Dreno B, Larkin J, Ribas A, et al
    5-Year Outcomes with Cobimetinib Plus Vemurafenib in BRAF (V600) Mutation-Positive Advanced Melanoma: Extended Follow-Up of the coBRIM Study.
    Clin Cancer Res. 2021 Jun 22. pii: 1078-0432.CCR-21-0809.
    PubMed         Abstract available

  3. WEISS SA, Djureinovic D, Jessel S, Krykbaeva I, et al
    A phase I study of APX005M and cabiralizumab with/without nivolumab in patients with melanoma, kidney cancer or non-small cell lung cancer resistant to anti-PD-(L)1.
    Clin Cancer Res. 2021 Jun 17. pii: 1078-0432.CCR-21-0903.
    PubMed         Abstract available


    Gene

  4. CHEN X, Gao J, Yu Y, Zhao Z, et al
    Retraction notice to "Long non-coding RNA UCA1 targets miR-185-5p and regulates cell mobility by affecting epithelial-mesenchymal transition in melanoma via Wnt/beta-catenin signaling pathway" [Gene 676 (2018) 298-305].
    Gene. 2021 Jun 17:145778. doi: 10.1016/j.gene.2021.145778.
    PubMed        


    J Am Acad Dermatol

  5. YOO H, Kim H, Kwon ST, Jo SJ, et al
    Tumor invasion in the hyponychium is associated with distant metastasis and poor prognosis in subungual melanoma: A histological landscape of 44 cases.
    J Am Acad Dermatol. 2021 Jun 18. pii: S0190-9622(21)01989.
    PubMed         Abstract available

  6. CARLET C, Dalle S, Leccia MT, Mortier L, et al
    Late-onset adverse events under anti-PD1 therapy in melanoma patients: an observational study from MELBASE, a nationwide prospective cohort.
    J Am Acad Dermatol. 2021 Jun 18. pii: S0190-9622(21)01991.
    PubMed         Abstract available


    J Clin Oncol

  7. HUPPERT LA, Daud AI
    Pembrolizumab and Ipilimumab as Second-Line Therapy for Advanced Melanoma.
    J Clin Oncol. 2021 Jun 17:JCO2100943. doi: 10.1200/JCO.21.00943.
    PubMed        


    Oncogene

  8. LEQUEUX A, Noman MZ, Xiao M, Van Moer K, et al
    Targeting HIF-1 alpha transcriptional activity drives cytotoxic immune effector cells into melanoma and improves combination immunotherapy.
    Oncogene. 2021 Jun 21. pii: 10.1038/s41388-021-01846.
    PubMed         Abstract available

  9. OTTINA E, Panova V, Doglio L, Kazachenka A, et al
    E3 ubiquitin ligase HECTD2 mediates melanoma progression and immune evasion.
    Oncogene. 2021 Jun 18. pii: 10.1038/s41388-021-01885.
    PubMed         Abstract available

  10. ALONSO-MARANON J, Villanueva A, Piulats JM, Martinez-Iniesta M, et al
    Combination of chemotherapy with BRAF inhibitors results in effective eradication of malignant melanoma by preventing ATM-dependent DNA repair.
    Oncogene. 2021 Jun 17. pii: 10.1038/s41388-021-01879.
    PubMed         Abstract available


    PLoS One

  11. WANG X, Asami S, Kitamura D
    A novel cancer immunotherapy using tumor-infiltrating B cells in the APCmin/+ mouse model.
    PLoS One. 2021;16:e0245608.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  12. ZHANG H, You X, Wang X, Cui L, et al
    Delivery of mRNA vaccine with a lipid-like material potentiates antitumor efficacy through Toll-like receptor 4 signaling.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: